Know all the prices and purchasing channels of avacopan

Avacopan (avacopan) is an innovative treatment for a specific type of vasculitis, providing a new treatment option for adults with severe active antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. This type of vasculitides, including granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), are rare autoimmune diseases that cause inflammation and damage of small or medium-sized blood vessels, affecting multiple vital organs such as the airways, kidneys, and lungs. The introduction of avacopan has brought hope to these patients.

Avacopan is primarily used as an adjunctive therapy in combination with standard therapies including corticosteroids. It is worth noting that although avacopan can enhance the therapeutic effect, it cannot completely replace glucocorticoids, and patients must continue to use glucocorticoids as directed by their doctor. In Europe, avacopan is also approved for use in combination with rituximab or cyclophosphamide for the treatment of adults with severely active GPA or MPA, further demonstrating its important role in the treatment of vasculitis.

From a mechanism of action perspective, avacopan is a selective antagonist of human complement5a receptor (C5aR1 or CD88). It can competitively inhibit the interaction between C5aR1 and anaphylatoxin C5a, thereby blocking the pro-inflammatory effect of C5a. C5a is a molecule that plays a key role in the inflammatory process. It can activate neutrophils, prompting them to migrate and adhere to the inflammatory site of small blood vessels. It also causes the retraction and increased permeability of vascular endothelial cells, further exacerbating inflammation. Avacopan can reduce these pro-inflammatory effects by specifically blocking C5aR1, thereby reducing vascular inflammation and damage.

The therapeutic effect of avacopan has been verified by multiple clinical studies. It not only reduces the symptoms of vasculitis but also improves patients’ quality of life. However, patients still need to remain vigilant when using avacopan and pay close attention to their physical condition and drug response. At the same time, because avacopan does not eliminate the need for glucocorticoids, patients still need to continue to use other treatments as directed by their doctor.

In summary, avacopan provides a new option for the treatment of ANCA-associated vasculitis. Its introduction not only enriches the treatment methods, but also brings more hope to patients. With the deepening of research and the accumulation of clinical experience, it is believed that avacopan will play a greater role in the future and bring good news to more patients. At the same time, we also look forward to the emergence of more innovative drugs to provide more possibilities for the treatment of rare diseases.

Avacopan is currently on the market in China, but due to its short time on the market, it may be difficult to purchase it directly. It is reported that there is a version of Avacopan available overseas, with a specification of 10mg*30 tablets and a price of about 15,000 yuan. If the patient needs to use this drug, it is recommended to consult a regular overseas medical consulting company.

Reference link:https://www.mayoclinic.org/zh-hans/drugs-supplements/avacopan-oral-route/description/drg-20524765